

Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Modified release doxycycline (Efracea®)	
Indication under review	Facial rosacea	
Policy No:	APC 107	
Date of Issue/Date of re-issue	September 2012, May 2015	
Review Date:	May 2018	
Policy Statement:		
Modified release doxycycline(Efracea®) is NOT indicated for the treatment of facial acne rosacea. The committee does not recommend treatment for patients except for a trial on consultant initiation in those rare cases where gastrointestinal side effects are preventing disease control.		
Traffic Light Status	Amber	Initiation on consultant specialist advice.
Key Points considered:		
<ul style="list-style-type: none"> • Evidence does not show the modified release preparation to be more effective than standard release preparations. • This policy has been produced as a guide for GPs. Evidence and information was carefully considered and consulted upon by clinicians who concluded that this treatment is not a cost effective use of scarce NHS resources. There are situations where this policy may not apply to an individual patient due to their clinical exceptionality. This policy statement does not overrule an individual GPs clinical decision making and therefore each GP would be need to make the final decision on whether treatment is a cost-effective use of their CCG budget. 		
References:		
<ol style="list-style-type: none"> 1. Valentin S.,Morales A.,Sanchez J.L.,Rivera A. Safety and efficacy of doxycycline in the treatment of rosacea. Clinical, Cosmetic and Investigational Dermatology, 2009, vol./is. 2/(129-140), 1178-7015 (2009) 2. Baldwin H.E.,Caveney S. Quality of life and treatment satisfaction in rosacea patients treated with doxycycline monohydrate 40 mg (30-mg Immediate release and 10-mg delayed-release beads) capsule-containing regimens. Seminars in Cutaneous Medicine and Surgery, March 2012, vol./is. 31/1(A11), 1085-5629 (March 2012) 3. Del Rosso J.Q.,Caveney S. Comparison of anti-inflammatory dose doxycycline (30-mg immediate-release beads, 10-mg delayed-release beads) vs. antibiotic dose doxycycline (100 mg) in the treatment of rosacea. Seminars in Cutaneous Medicine and Surgery, March 2012, vol./is. 31/1(A7-A8), 1085-5629 (March 2012) 		
Date taken to EPC:	September 2012	
Expired policy reviewed by APC	6 th May 2015	
Date Ratified by GP MOC	17 th June 2015	